Drug Profile
Research programme: aurora kinase inhibitors - Merck
Alternative Names: SCH-1473759Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Pyrazines; Small molecules
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 26 Aug 2010 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours presented at the 240th American Chemical Society National Meeting ,
- 21 Apr 2010 Preclinical trials in Solid tumours in USA (unspecified route)